Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $2.2 million.

  • Cartesian Therapeutics' Accounts Payables rose 33036.75% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 33036.75%. This contributed to the annual value of $288000.0 for FY2024, which is 9085.71% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Accounts Payables of $2.2 million as of Q3 2025, which was up 33036.75% from $454000.0 recorded in Q2 2025.
  • Cartesian Therapeutics' Accounts Payables' 5-year high stood at $3.2 million during Q4 2023, with a 5-year trough of $154000.0 in Q2 2021.
  • Its 5-year average for Accounts Payables is $1.0 million, with a median of $517000.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in Cartesian Therapeutics' Accounts Payables was 97191.01% (2024), while the steepest drop was 9085.71% (2024).
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Accounts Payables stood at $224000.0 in 2021, then soared by 41.07% to $316000.0 in 2022, then surged by 896.84% to $3.2 million in 2023, then plummeted by 90.86% to $288000.0 in 2024, then skyrocketed by 672.57% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $454000.0 for Q2 2025, and $2.1 million during Q1 2025.